Source comparison
Peptides for Fat Loss Research: Category Comparison
Researchers selecting peptides for fat loss studies must match compound mechanism to experimental endpoints—GLP-1 agonists for appetite and gastric studies, GH secretagogues for lipolysis and body composition, AMPK modulators for metabolic pathway investigatio
This comparison does not assign a generated winner or score.
- Researchers selecting peptides for fat loss studies must match compound mechanism to experimental endpoints—GLP-1 agonists for appetite and gastric studies, GH secretagogues for lipolysis and body composition, AMPK modulators for metabolic pathway investigation.
- GLP-1 Receptor Agonists (semaglutide, tirzepatide, survodutide)
- Slows gastric emptying, activates hypothalamic satiety pathways, reduces ghrelin rebound
- 5–7 days (long-acting analogs)
- 0.25–2.4 mg/week (scaled to body weight)
- Body weight, food intake, gastric emptying time, plasma GLP-1 levels
- Best for studies investigating appetite regulation, meal timing effects, and total weight loss—produces the largest magnitude effect in obesity models
- GH Secretagogues (ipamorelin, CJC-1295, tesamorelin, sermorelin)
- Stimulates pulsatile growth hormone release, activates hormone-sensitive lipase in adipocytes
- 2 hours (ipamorelin) to 6–8 days (CJC-1295)
- 100–300 mcg/dose for short-acting; 1–2 mg/week for long-acting
- Serum GH and IGF-1 levels, visceral adipose tissue volume, lean mass, lipolysis markers
- Best for body composition studies—produces targeted visceral fat reduction with lean mass preservation, ideal for investigating GH-mediated lipolysis
- Dual/Triple Agonists (retatrutide, mazdutide)
- GLP-1 + GIP ± glucagon receptor agonism—combines appetite suppression, insulin sensitivity, thermogenesis
- 5–7 days
- 0.5–12 mg/week (dose-escalation protocols)
- Body weight, energy expenditure, insulin sensitivity (HOMA-IR), adipocyte metabolism markers
- Best for mechanistic studies investigating receptor crosstalk—produces the greatest total weight loss but requires careful titration to manage side effects
- AMPK Activators (5-Amino-1MQ)
- Inhibits NNMT, restores NAD+ levels, activates AMPK pathway for fatty acid oxidation
- 4–6 hours (estimated, early-phase compound)
- 50–100 mg/day (oral dosing in preclinical models)
- NAD+ levels, AMPK phosphorylation, respiratory quotient, fat mass via imaging
- Best for metabolic pathway investigation—produces fat loss without appetite suppression, useful for isolating mitochondrial and NAD+-dependent mechanisms
- Lipotropic Compounds (Lipo C, methionine-inositol-choline combinations)
- Supports hepatic lipid metabolism, methyl donor for fat transport
- N/A (amino acids and cofactors, not peptides)
- Varies by formulation
- Hepatic triglyceride content, lipid panel markers
- Adjunct only—does not produce significant fat mass reduction independently; used to support liver function during fat mobilization
- GLP-1 agonists dominate current research because they produce the largest effect size—15–24% body weight reduction in clinical trials—and target a well-characterized pathway with extensive safety data. GH secretagogues offer more targeted body composition changes, particularly visceral fat reduction with lean mass preservation, making them valuable for studies where total weight loss is not the primary endpoint. Dual and triple agonists represent the mechanistic frontier—combining pathways that independently contribute to fat loss—but require more complex dosing protocols and produce higher rates of gastrointestinal adverse events during titration.